Abbott Laboratories Quick Ratio (ABT) starting from the first quarter 2026 to first quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Abbott Laboratories  (NYSE: ABT)

Abbott Laboratories's Quick Ratio

ABT's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the first quarter 2026, Quick Ratio fell to 0.67 above Abbott Laboratories average.

Within Major Pharmaceutical Preparations industry 374 other companies have achieved higher Quick Ratio than Abbott Laboratories in first quarter 2026. While Quick Ratio total ranking in the first quarter 2026 has deteriorated compared to the prior quarter from 0 to 2064.

Explain Quick Ratio?
How much Cash & cash equivalents ABT´s has?
What are ABT´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ABT Quick Ratio (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2		 (Mar 31 2025)
Q1
Y / Y Current Liabilities Change 71.03 % -17.05 % -9.94 % -25.55 % -30.6 %
Y / Y Cash & cash equivalent Change 6.59 % 12.2 % -0.71 % 0.87 % 2.9 %
Quick Ratio MRQ 0.67 0.93 1.01 1.08 1.07
ABT's Total Ranking # 2064 # 0 # 0 # 0 # 0
Seq. Current Liabilities Change 13.67 % 24.96 % 13.61 % 5.98 % -44.87 %
Seq. Cash & cash equivalent Change -18.39 % 15.6 % 6.19 % 6.4 % -14.1 %



Quick Ratio first quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 375
Healthcare Sector # 683
Overall Market # 2064


Quick Ratio Statistics
High Average Low
2.82 0.6 0.11
(Dec 31 2016)   (Dec. 31. 2006)




Financial Statements
Abbott Laboratories's Current Liabilities $ 10,898 Millions Visit ABT's Balance sheet
Abbott Laboratories's Cash & cash equivalent $ 7,295 Millions Visit ABT's Balance sheet
Source of ABT's Sales Visit ABT's Sales by Geography


Cumulative Abbott Laboratories's Quick Ratio

ABT's Quick Ratio for the trailling 12 Months

ABT Quick Ratio

 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months		 (Mar 31 2025)
12 Months
Y / Y Current Liabilities TTM Growth -1.71 % -20.73 % -12.71 % -6.09 % -12.59 %
Y / Y Cash & cash equivalent TTM Growth 4.8 % 3.96 % 3.07 % 5.98 % 2.35 %
Quick Ratio TTM 0.9 1.01 0.92 0.9 0.84
Total Ranking TTM # 4052 # 0 # 0 # 0 # 0
Seq. Current Liabilities TTM Growth 14.9 % -6.09 % -2.55 % -6.52 % -7.33 %
Seq. Cash & cash equivalent TTM Growth 1.46 % 3.26 % -0.18 % 0.21 % 0.65 %

Quick ratio ranking by company, industry and sector >> Back to ABT Financial Strength Comparisons >> Go to Compare ABT Quick Ratio to its Competitors

On the trailing twelve months basis Due to increase in Current Liabilities in the Q1 2026 to $10,898.00 millions, cumulative Quick Ratio decreased to 0.9 above the ABT average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 435 other companies have achieved higher Quick Ratio than Abbott Laboratories. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2025 from 0 to 4052.

Explain Quick Ratio?
How much Cash & cash equivalents ABT´s has?
What are ABT´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 436
Healthcare Sector # 898
Within the Market # 4052


trailing twelve months Quick Ratio Statistics
High Average Low
1.74 0.58 0.13
(Sep 30 2017)   (March 31, 2007)




Companies with similar Quick Ratio in the quarter ending Mar 31 2026, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2026 MRQ Cash & cash equivalentMar 31 2026 MRQ Current Liabilities
Cryoport inc   1.80 $ 405.680  Millions$ 224.867  Millions
Amphastar Pharmaceuticals Inc   1.79 $ 294.151  Millions$ 164.478  Millions
60 Degrees Pharmaceuticals Inc   1.79 $ 3.338  Millions$ 1.867  Millions
Gossamer Bio Inc   1.76 $ 99.215  Millions$ 56.506  Millions
Actuate Therapeutics Inc   1.72 $ 8.134  Millions$ 4.722  Millions
Decoy Therapeutics Inc   1.72 $ 7.821  Millions$ 4.546  Millions
Therapeuticsmd Inc   1.71 $ 8.419  Millions$ 4.911  Millions
Cellectar Biosciences Inc   1.71 $ 8.347  Millions$ 4.874  Millions
Matinas Biopharma Holdings Inc   1.71 $ 2.398  Millions$ 1.406  Millions
Sarepta Therapeutics Inc   1.70 $ 653.189  Millions$ 383.127  Millions
Lantern Pharma Inc   1.70 $ 6.323  Millions$ 3.718  Millions
Puma Biotechnology Inc   1.70 $ 101.545  Millions$ 59.737  Millions
Petros Pharmaceuticals inc   1.66 $ 4.352  Millions$ 2.623  Millions
Hyperion Defi inc   1.65 $ 7.381  Millions$ 4.473  Millions
Cyclerion Therapeutics Inc   1.65 $ 2.823  Millions$ 1.714  Millions
Zai Lab Limited  1.65 $ 660.092  Millions$ 401.067  Millions
Skye Bioscience Inc   1.64 $ 17.109  Millions$ 10.405  Millions
Rigel Pharmaceuticals Inc  1.64 $ 146.684  Millions$ 89.492  Millions
Ultragenyx Pharmaceutical Inc   1.63 $ 413.000  Millions$ 253.000  Millions
Connect Biopharma Holdings Limited  1.62 $ 6.674  Millions$ 4.118  Millions
Indaptus Therapeutics Inc   1.61 $ 1.498  Millions$ 0.933  Millions
Seres Therapeutics Inc   1.54 $ 29.834  Millions$ 19.344  Millions
Apimeds Pharmaceuticals US, Inc.  1.52 $ 11.459  Millions$ 7.525  Millions
Quantum Cyber N v   1.51 $ 4.450  Millions$ 2.951  Millions
Apellis Pharmaceuticals Inc   1.47 $ 405.207  Millions$ 276.486  Millions
Protagenic Therapeutics Inc new  1.46 $ 1.509  Millions$ 1.031  Millions
Phathom Pharmaceuticals Inc   1.45 $ 180.904  Millions$ 125.041  Millions
Novo Nordisk A  1.43 $ 3,257.223  Millions$ 2,282.230  Millions
Cormedix Inc   1.42 $ 178.087  Millions$ 125.600  Millions
Mirum Pharmaceuticals Inc   1.42 $ 386.259  Millions$ 272.824  Millions

Date modified: 2026-09-26T07:14:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.